GlassScriptPhysician profile
Griffin Murray
NPI 1003540709
$9,044.07
in general payments reported to CMS, 2019-2025
55 companies · $2,116 in 2025
The $2,116 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,260 · 2023: $2,896 · 2024: $2,772 · 2025: $2,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,723 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,723.11 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,041.18 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $933.94 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $804.02 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $605.36 | 2022-2025 | |
| Exact Sciences Corporation | $470.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $454.72 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $450.91 | 2022-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.98 | 2022-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Pfizer INC. | $340.21 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $316.02 | 2023-2025 | Xifaxan |
| Amgen INC. | $291.78 | 2023-2025 | Repatha, Otezla, Evenity |
| Axsome Therapeutics, INC. | $232.03 | 2023-2025 | Auvelity |
| Alk-Abello, INC | $193.27 | 2024-2025 | Grastek, Ragwitek, Odactra |
| Vanda Pharmaceuticals INC. | $168.12 | 2022-2023 | Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.17 | 2025 | Caplyta |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Griffin Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.